Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.48 |
| ▸ | CNR1 | P21554 | 10/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418676 | 0.83 | JUN (0.51) | CNR2CNR1JUNNFKB1NFKB2 | |
| SCHEMBL6415912 | 0.78 | CNR2 (0.62) | CNR2CNR1ANO1 | |
| SCHEMBL6415338 | 0.77 | CNR2 (0.51) | CNR2CNR1KMT2A | |
| SCHEMBL16702069 | 0.77 | JUN (0.46) | CNR2JUNNFKB1NFKB2RELA | |
| SCHEMBL30553734 | 0.77 | JUN (0.59) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL20460466 | 0.76 | JUN (0.48) | CNR2JUNNFKB1NFKB2RELA | |
| SCHEMBL936146 | 0.75 | JUN (0.47) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL18130923 | 0.75 | CNR2 (0.52) | CNR2CNR1JUNNFKB1NFKB2 | |
| SCHEMBL667384 | 0.74 | NFKB1 (0.51) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL31306809 | 0.74 | P2RX7 (0.52) | JUNNFKB1NFKB2RELAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1278167-A | Amide derivatives | SUMITOMO PHARMA (JP) | 2000-12-27 | — | — | CN | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | CNR2 183/4885CNR1 206/4885JUN 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.